Clinical trial

Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient

NCT02069418

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

RADIATION · Unmapped registry intervention 18F-FLT-TEP Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention 18F-FDG-TEP Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2014-02-01

PhasePHASE2

Conditions

Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrentunresolved

No EGFR Activating Mutationunresolved

Interventions

18F-FLT-TEPRADIATION

18F-FDG-TEPRADIATION

Sponsors & collaborators

University Hospital, Angerslead sponsor

University Hospital, Tourscollaborator

Army Hospital, Percycollaborator

Créteil Hospitalcollaborator

University Hospital, Rouencollaborator

Central Hospital, Nancy, Francecollaborator

University Hospital, Toulousecollaborator

University Hospital, Bordeauxcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02069418 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.